Q&A – Oxipit acquisition
This Q&A is intended to provide clear and transparent information regarding Sectra’s acquisition of Oxipit.
Information last updated: April 15, 2026
In March 2026, Sectra announced the agreement to acquire Oxipit, UAB, a medical AI company based in Vilnius, Lithuania. In April 2026 Sectra announced the acquisition had been finalized.
Oxipit is a European medical AI company specializing in imaging solutions designed to support – and in certain cases autonomously handle – clearly defined diagnostic workflows.
Oxipit offers radiology AI solutions across chest X-ray, chest CT, and musculoskeletal X-ray. The portfolio includes tools for workflow support, triage, and quality assurance – and in selected cases, autonomous handling of routine studies.
Decision-support AI assists clinicians by highlighting potential findings. Autonomous AI is designed to independently manage specific, well-defined cases when strict safety criteria are met. Both approaches play important roles in future clinical workflows.
Sectra acquired Oxipit to strengthen our capabilities in clinical AI and accelerate the safe and scalable deployment of AI in healthcare. Oxipit brings proven technology, strong intellectual property, and a highly specialized team. By combining this with Sectra’s global customer base and market access, we can bring these solutions to more healthcare providers faster.
Oxipit combines proven technology, regulatory progress, and deep domain expertise with a strong focus on clinical autonomy. Their approach aligns well with Sectra’s ambition to enable reliable, real-world deployment of AI in healthcare. Equally important, Oxipit brings a highly specialized team whose competence complements Sectra’s platform and global reach.
Autonomous reporting, when implemented with appropriate clinical governance and oversight, has the potential to significantly improve efficiency in radiology departments while maintaining diagnostic quality. Sectra sees high-confidence autonomous reporting in selected imaging workflows as a capability that will be broadly needed across healthcare. This agreement reflects a commitment to making it a central part of what Sectra delivers.
Yes. Sectra Amplifier Marketplace remains an open, vendor-neutral ecosystem. Our goal is to offer the best ecosystem for customers, not limit choice. Our partners continue operating as before. This acquisition adds to Sectra’s own capability in one specific area alongside – not instead of – our partners.
No, a strong partner ecosystem remains critical to our strategy
No. Our goal is to offer the best ecosystem for customers – not limit choice.
As Oxipit is now officially a part of the Sectra group, relationships are now managed by Sectra. No immediate change of contact-persons or communication paths.
Yes, as Oxipit is now officially a part of the Sectra group, existing partner relationships and contractual commitments are now managed by Sectra. No immediate change of contact-persons or communication paths.
No immediate changes are made to how Oxipit solutions are sold.